Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Downey

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
International Journal of Molecular Sciences|May 25, 2024
Initial Despair and Current Hope of Identifying a Clinically Useful Treatment of Myocardial Reperfusion Injury: Insights Derived from Studies of Platelet P2Y<sub>12</sub> Antagonists and Interference with Inflammation and NLRP3 AssemblyMichael V Cohen, James M Downey
Journal of Molecular and Cellular Cardiology|October 4, 2005
Unraveling the mysteries of classical preconditioningJames M Downey, Michael V Cohen
Progress in Cardiovascular Diseases|April 22, 2006
Reducing infarct size in the setting of acute myocardial infarctionJames M Downey, Michael V Cohen
Circulation Journal : Official Journal of the Japanese Circulation Society|June 10, 2009
Why do we still not have cardioprotective drugs?James M Downey, Michael V Cohen
Circulation Research|January 2, 2009
O-linked beta-N-acetylglucosamine: a new piece of the cardioprotection puzzle?James M Downey, Michael V Cohen
Circulation|April 26, 2017
Letter by Downey and Cohen Regarding Article, "Protective Effects of Ticagrelor on Myocardial Injury After Infarction"James M Downey, Michael V Cohen
Physiological Reviews|September 25, 2003
Preconditioning the myocardium: from cellular physiology to clinical cardiologyDerek M Yellon, James M Downey
Basic Research in Cardiology|November 14, 2007
Adenosine: trigger and mediator of cardioprotectionMichael V Cohen, James M Downey
Circulation|September 19, 2007
Bypassing big pharmaJames M Downey, Michael V Cohen
Journal of the American College of Cardiology|March 21, 2006
AMISTAD trials: possible reasons for lack of successMichael V Cohen, James M Downey
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
International Journal of Molecular Sciences|May 25, 2024
Initial Despair and Current Hope of Identifying a Clinically Useful Treatment of Myocardial Reperfusion Injury: Insights Derived from Studies of Platelet P2Y<sub>12</sub> Antagonists and Interference with Inflammation and NLRP3 AssemblyMichael V Cohen, James M Downey
Journal of Molecular and Cellular Cardiology|October 4, 2005
Unraveling the mysteries of classical preconditioningJames M Downey, Michael V Cohen
Progress in Cardiovascular Diseases|April 22, 2006
Reducing infarct size in the setting of acute myocardial infarctionJames M Downey, Michael V Cohen
Circulation Journal : Official Journal of the Japanese Circulation Society|June 10, 2009
Why do we still not have cardioprotective drugs?James M Downey, Michael V Cohen
Circulation Research|January 2, 2009
O-linked beta-N-acetylglucosamine: a new piece of the cardioprotection puzzle?James M Downey, Michael V Cohen
Circulation|April 26, 2017
Letter by Downey and Cohen Regarding Article, "Protective Effects of Ticagrelor on Myocardial Injury After Infarction"James M Downey, Michael V Cohen
Physiological Reviews|September 25, 2003
Preconditioning the myocardium: from cellular physiology to clinical cardiologyDerek M Yellon, James M Downey
Basic Research in Cardiology|November 14, 2007
Adenosine: trigger and mediator of cardioprotectionMichael V Cohen, James M Downey
Circulation|September 19, 2007
Bypassing big pharmaJames M Downey, Michael V Cohen
Journal of the American College of Cardiology|March 21, 2006
AMISTAD trials: possible reasons for lack of successMichael V Cohen, James M Downey
Pageof 12